These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1077 related items for PubMed ID: 31099402

  • 1. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L.
    Acta Derm Venereol; 2019 Sep 01; 99(10):851-857. PubMed ID: 31099402
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, Kawashima M, Ferrándiz C, Smith CH, Beck LA, Chan KC, Chen Z, Akinlade B, Hultsch T, Staudinger H, Gadkari A, Eckert L, Davis JD, Rajadhyaksha M, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Ardeleanu M.
    JAMA Dermatol; 2020 Feb 01; 156(2):131-143. PubMed ID: 31876900
    [Abstract] [Full Text] [Related]

  • 3. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B.
    Lancet; 2017 Jun 10; 389(10086):2287-2303. PubMed ID: 28478972
    [Abstract] [Full Text] [Related]

  • 4. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
    Offidani A, Stingeni L, Neri I, Cipriani F, Chen Z, Rossi AB, Lu Y, Moretti D.
    Ital J Dermatol Venerol; 2022 Feb 10; 157(1):39-46. PubMed ID: 33878856
    [Abstract] [Full Text] [Related]

  • 5. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B.
    Br J Dermatol; 2018 May 10; 178(5):1083-1101. PubMed ID: 29193016
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS, Pinter A, Wine Lee L, Aschoff R, Zdybski J, Schnopp C, Praestgaard A, Bansal A, Shumel B, Prescilla R, Bastian M.
    Adv Ther; 2024 Mar 10; 41(3):1046-1061. PubMed ID: 38194047
    [Abstract] [Full Text] [Related]

  • 7. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR.
    N Engl J Med; 2014 Jul 10; 371(2):130-9. PubMed ID: 25006719
    [Abstract] [Full Text] [Related]

  • 8. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP.
    J Am Acad Dermatol; 2021 Jan 10; 84(1):139-147. PubMed ID: 32822798
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M.
    Lancet; 2016 Jan 02; 387(10013):40-52. PubMed ID: 26454361
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
    Zheng Y, Ding RL, Bu J.
    Front Immunol; 2024 Jan 02; 15():1367099. PubMed ID: 38812522
    [Abstract] [Full Text] [Related]

  • 11. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.
    Thomson J, Wernham AGH, Williams HC.
    Br J Dermatol; 2018 Apr 02; 178(4):897-902. PubMed ID: 29315479
    [Abstract] [Full Text] [Related]

  • 12. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, Guillemin I, Chen Z, Ardeleanu M, Bansal A, Kaur M, Rossi AB, Graham NMH, Patel N, Gadkari A.
    J Am Acad Dermatol; 2020 Jun 02; 82(6):1328-1336. PubMed ID: 32135208
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
    Paller AS, Silverberg JI, Cork MJ, Guttman-Yassky E, Lockshin B, Irvine AD, Kim MB, Kabashima K, Chen Z, Lu Y, Bansal A, Rossi AB, Shabbir A.
    JAMA Dermatol; 2023 Mar 01; 159(3):255-266. PubMed ID: 36723913
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A.
    Am J Clin Dermatol; 2022 May 01; 23(3):365-383. PubMed ID: 35567671
    [Abstract] [Full Text] [Related]

  • 15. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, Kamsteeg M, Giovannone B, Drylewicz J, van Amerongen CCA, Delemarre EM, Knol EF, van Wijk F, Nierkens S, Thijs JL, Schuttelaar MLA, de Bruin-Weller MS.
    Allergy; 2020 Jan 01; 75(1):116-126. PubMed ID: 31593343
    [Abstract] [Full Text] [Related]

  • 16. Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
    Simpson EL, Pink AE, Blauvelt A, Gooderham M, Armstrong AW, Worm M, Katoh N, Peris K, Puig L, Barbarot S, Mark T, Steffensen LA, Tindberg AM, Wollenberg A.
    Am J Clin Dermatol; 2023 Nov 01; 24(6):939-952. PubMed ID: 37682422
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
    Boesjes CM, Kamphuis E, de Graaf M, Spekhorst LS, Haeck I, van der Gang LF, Loman L, Zuithoff NPA, Dekkers C, van der Rijst LP, Romeijn GLE, Oosting AJ, Gostynksi A, van Lynden-van Nes AMT, Tupker RA, van Tuyll van Serooskerken AM, Flinterman A, Politiek K, Touwslager WRH, Christoffers WA, Stewart SM, Kamsteeg M, Schuttelaar MA, de Bruin-Weller MS.
    JAMA Dermatol; 2024 Oct 01; 160(10):1044-1055. PubMed ID: 39110432
    [Abstract] [Full Text] [Related]

  • 18. Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis.
    Torres T, Sohrt Petersen A, Ivens U, Bosch Vilaro A, Stinson J, Carrascosa JM.
    Dermatol Ther (Heidelb); 2024 Apr 01; 14(4):983-992. PubMed ID: 38613642
    [Abstract] [Full Text] [Related]

  • 19. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA, Deleuran M, Bissonnette R, de Bruin-Weller M, Galus R, Nakahara T, Seo SJ, Khokhar FA, Vakil J, Xiao J, Marco AR, Levit NA, O'Malley JT, Shabbir A.
    Am J Clin Dermatol; 2022 May 01; 23(3):393-408. PubMed ID: 35503163
    [Abstract] [Full Text] [Related]

  • 20. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J.
    J Drugs Dermatol; 2018 Jul 01; 17(7):750-756. PubMed ID: 30005097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.